Author Of 1 Presentation
P0425 - A real-world analysis of ocrelizumab treatment patterns among multiple sclerosis patients in Saskatchewan, Canada (ID 1443)
Abstract
Background
Ocrelizumab is a high-efficacy disease-modifying therapy (DMT) used for the treatment of multiple sclerosis (MS), which was recently added to the Saskatchewan (SK) formulary in May 2019. This medication has been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). However, there is limited data available on treatment patterns that could guide real-world clinical decision-making.
Objectives
To describe real-world evidence and treatment patterns of ocrelizumab in patients with multiple sclerosis in Saskatchewan, Canada.
Methods
We retrospectively collected data of research consented patients visiting the SK MS clinic who were ≥ 18 years of age with a confirmed diagnosis of MS and had received at least one treatment cycle of ocrelizumab. Data was extracted from our clinical electronic medical records and analyzed using SPSS.
Results
The study cohort consisted of 116 patients with the following demographics: mean age: 42.13 ± 10.5 years, 69 (59.5%) female, median expanded disability status scale (EDSS): 2.5 (0–6.5), and mean disease duration: 10.13 ± 7.7 years. The cohort received a median of 2 (1-5) ocrelizumab cycles at a mean duration of 9.22 ± 7.7 years from disease onset. Twenty two patients (19%) had PPMS, 92 patients (79.3%) had RRMS and 2 patients (1.7%) had active progressive MS. Fifty three patients (45.7%) were treatment naïve. The numbers of DMTs used in patients prior to switching to ocrelizumab were: one in 32 patients (27.6%); two in 16 patients (13.8%); three in 8 patients (6.9%); four in 5 patients (4.3%) and one patient (0.9%) each for five and seven DMTs. 22 patients (19%) switched from dimethyl fumarate; followed by 11 patients (9.5%) from glatiramer acetate, 9 patients (7.8%) from teriflunomide, 6 patients (5.2%) from interferon-beta 1a, 5 patients (4.3%) from natalizumab, 4 patients (3.4%) from alemtuzumab, 3 patients (2.6%) from fingolimod and 2 patients (1.7%) from interferon-beta 1b. The most common reasons for switching were adverse events and persistence of relapses. Infusion reactions were observed in 24 patients (20.7%) who started on ocrelizumab; with the most common presenting symptoms of fatigue, headache, nausea and throat irritation. Twenty four patients had a comorbid diagnosis of depression.
Conclusions
The majority of patients who started on ocrelizumab had RRMS. The most common reason to switch to ocrelizumab was due to adverse events or persistence of relapses.